chang earn forecast
engin fire give visibl
organ medium term
organ revenue guidanc came st
overal compar rev stj acceler bp
stj grow
us rhythm manag impress mitraclip grew
confirm icm strong start contribut hundr bp
strong free cash convers even
improv expect
gross oper margin came expect
manag point mix impact alr epd
account chang pension incom move line impact
report oper margin optic seem declin
libr contribut mm us weight
thesi updat larg cap compani trade north price-to-earnings
level need strong case sustain revenu trend maintain
multipl disappoint organ revenu
acceler plu organ revenue guidanc give comfort
sustain strength especi driven new product
launch product includ mri launch confirm icm
ep mitraclip improv nutrit continu share gain dx
look contribut alin continu
mitraclip strength coapt trial catalyst libr us ramp
continu improv nutrit give comfort could
sustain top-line addit manag comment
would reinvest tax reform benefit also provid confid
debt paydown faster expect execut synergi front
enabl drive doubl digit ep growth next year
teen tsr along dividend yield understand
multipl punchi think level visibl larg cap land
rare allow trade premium market
reiter outperform rate share rais pt
next page talk point
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
diagnost mid high singl digit growth
aler call rapid diagnost contribut littl
medic devic mid high singl digit growth
foreign exchang favor impact littl
gross margin somewhat
sg margin somewhat reflect pension reclassif
invest busi
non oper incom mm includ pension relat net incom reclassifi
cog sg
aler call rapid diagnost contribut littl
medic devic mid high singl digit growth
foreign exchang favor impact around
gross margin somewhat
emerg market favor macro dynam socioeconom trend expand middl class
nutrit global nutrit market bn favor trend drive growth
neuromodul expect market growth fy
recent launch product benefit beyond
diagnost alin launch continu began europ continu
geographi
devic initi physician feedback confirm rx posit think could
contribut mm fy
repaid approxim bn debt januari bring total debt approxim bn
pay addit bn next month
expect gross debt level net debt level end
like increas dividend end maintain dividend pay-out ratio
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst vijay kumar brittani henderson primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
